about
Protein dynamics of the HIF-2α PAS-B domain upon heterodimerization and ligand bindingDevelopment of a multisite model for Ni(II) ion in solution from thermodynamic and kinetic data.A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulation.Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds.Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3σ case.Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors.Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents.Structure-based design of small-molecule protein-protein interaction modulators: the story so far.Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin-Based Derivatives.Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases.Chalcone-based carbamates for Alzheimer's disease treatment.Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors.Kernel-Based, Partial Least Squares Quantitative Structure-Retention Relationship Model for UPLC Retention Time Prediction: A Useful Tool for Metabolite Identification.N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl.Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation.Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.Design and synthesis of thiadiazoles and thiazoles targeting the Bcr-Abl T315I mutant: from docking false positives to ATP-noncompetitive inhibitors.Pharmacophore modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid-glutamic acid-alanine-aspartic acid box polypeptide 3.Next generation of antiretroviral agents targeting the RNA binding site of the HIV-1 cellular cofactor DDX3: an innovative therapeutic approach.Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.Synthesis of natural urolithin M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A.Protein Tunnels: The Case of Urease Accessory Proteins.Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway EpitheliaCollecting and assessing human lactate dehydrogenase-A conformations for structure-based virtual screeningFrom AChE to BACE1 inhibitors: The role of the amine on the indanone scaffoldInhibitors of human immunodeficiency virus-1 replication targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase
P50
Q28537917-ACC6EDAF-C38E-493E-8CEF-8EFCC010C86FQ30101000-CCD2696C-2AA9-4D06-B9D8-032CD0685FEDQ31078016-863AC5DA-78CE-43C6-97A5-BFF54FF2A65EQ33310225-EEF810B0-5A8E-4C24-8A71-2C6611CD3981Q33351239-2661DCAF-0E82-4175-85EE-B0AABD22AD71Q33438089-88BA3546-1F6B-4436-8350-4435D0FF067AQ34036525-C235489C-57AA-4248-9050-5C29D62451F5Q34149154-1FF74B20-B95E-482A-A0C0-30BE34C9FBE4Q34787546-0AAC931A-C38F-4576-B0F0-B94D51336460Q35103944-D94C49F8-3892-4BDF-B1E8-E843774337E2Q35617834-D3DD7524-C159-4BDD-87FA-9C7A2260FEA6Q35734971-DDBDCD58-60CF-4286-8392-FA6DD73DBC7BQ35823536-F05965B3-37AA-4AF6-99EB-42BC54160625Q36260001-738E97A1-59B3-4A08-9663-A6114E4AB8C4Q38684584-E7E703A3-F8FA-4FA6-AA86-B621215288E6Q38859786-EA847157-1B29-4DA5-A0AE-B4658D620E83Q39432697-434ED0ED-DAAD-45BF-B8B9-EB0023423B0AQ39459749-FFC9FB37-747B-4FF7-AC15-95C1FE616632Q39519625-9A2B2924-B5D2-4E52-A9B4-04392886F667Q41739570-E121FB64-E890-4A07-93BB-D82E59D30B25Q43051637-32824FA9-8598-444F-A9BA-EA4119109BFFQ45390419-0B608FF9-ED18-43FA-8376-4F004693A08DQ45911766-06C81C21-38FC-4472-B60F-C22A8F61A88CQ47906276-203A7616-B087-438E-8C4E-96D319C9C21DQ48053265-D95D477F-A06A-471E-A966-FD4820B9728DQ48317453-DF290EF6-CF54-4951-98C4-F99CB55DC4B7Q50067828-94877CC0-1F03-4696-855F-FD6395C1575AQ56363938-EF5C6515-F456-4AED-96ED-B401BB512A4CQ56976736-D0F5B688-984C-404D-B3A4-CDA05B13C05AQ58010763-2E7E7AB3-D39A-413A-BBE1-C361049B2277Q59254100-6DD32513-14FA-4584-8677-CF36D62FA25B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Federico Falchi
@ast
Federico Falchi
@en
Federico Falchi
@es
Federico Falchi
@nl
Federico Falchi
@sl
type
label
Federico Falchi
@ast
Federico Falchi
@en
Federico Falchi
@es
Federico Falchi
@nl
Federico Falchi
@sl
prefLabel
Federico Falchi
@ast
Federico Falchi
@en
Federico Falchi
@es
Federico Falchi
@nl
Federico Falchi
@sl
P1053
Q-6970-2016
P106
P1153
23481517200
P21
P31
P3829
P496
0000-0001-7385-649X